ORANGE, CA – Robert Thomas Freeman, the Chief Financial Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), has recently completed transactions involving the company's common stock, according to the latest regulatory filings. On March 13, Freeman acquired a significant number of shares, and on March 15, he sold a portion of his holdings for a total value of $57,998.
The sale involved 11,858 shares at a weighted-average price range of $4.77 to $5.06, with the average price per share being $4.8911. This transaction was not made at Freeman's discretion; instead, it was required to cover tax withholding obligations related to the vesting of restricted stock units. The total number of shares Freeman owned following this transaction decreased to 898,228.
On the buying side, Freeman acquired a total of 200,710 shares, which included 110,000 restricted stock units that will vest over a four-year period, 21,000 fully vested shares awarded by the company's Board of Directors, and 69,710 fully vested shares granted in lieu of cash for the annual incentive award. These acquisitions were valued at $0, as they were part of compensation and did not involve a direct purchase at market prices.
Additionally, the filing disclosed that Freeman has an indirect beneficial interest in 519,429 shares held by FCO Holdings LLC, which is owned by FCO Holdings Trust One.
Investors often monitor insider transactions such as these for insights into executive confidence and company performance. Alignment Healthcare, Inc. continues to be transparent with its executive dealings, providing detailed information on these transactions to the public and regulatory bodies.
For further information regarding the specific details of the shares sold at each price within the range, Freeman has agreed to provide full information upon request to Alignment Healthcare, Inc., its security holders, or the Securities and Exchange Commission staff.
InvestingPro Insights
As investors consider the insider transactions of Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman, it may be beneficial to look at the broader financial health and market performance of the company. Here are some key insights from InvestingPro that could provide additional context to the recent stock activities:
Alignment Healthcare holds a market capitalization of approximately $943 million, which is a significant figure that reflects the company's size and market value. Despite this, analysts have identified concerns, as indicated by two of them revising their earnings expectations downwards for the upcoming period. This could suggest that investors might need to brace for potential dips in the company's financial performance.
One of the InvestingPro Tips highlights that Alignment Healthcare is currently trading at a low revenue valuation multiple, which may signal an undervaluation of the company's stock relative to its revenue generation. This could be an attractive point for investors looking for potential growth opportunities. Moreover, the company is trading near its 52-week low, which might indicate a buying opportunity for those who believe in the long-term prospects of the firm, despite the lack of profitability over the last twelve months and the absence of dividend payments to shareholders.
From a financial metrics standpoint, the company's Price / Book ratio stands at 6.01 as of the last twelve months, which is relatively high and suggests that the market is pricing the company's assets at a premium. Additionally, the company's revenue growth was 27.16% over the same period, a strong sign of business expansion that investors typically view positively.
For those interested in a deeper analysis, there are an additional 9 InvestingPro Tips available at InvestingPro. These tips could provide further guidance on the stock's outlook. To access these insights and more, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.